RP9 revisited; RP9 p.(H137L) remains a likely cause of dominant splicing factor-Retinitis Pigmentosa.
Chang L
Genomic medicine is already helping more people receive answers about their health conditions through better diagnosis, treatment, and support. By volunteering to take part in research, you'll be making a difference to NHS patients and the future of genomic medicine.
Research in this community will focus on the development, refinement, validation and application of bioinformatics approaches to interrogate data in the NGRL and maximise the ability for clinically relevant discovery. It will facilitate the open exchange and sharing of computational ideas and methods, including powerful machine learning approaches. It will also ensure best practices in clinical interpretation analysis, work with disease groups to provide access to world-leading statistical and computational data analysis expertise; and provide training and support a world-leading workforce in support of genomic-based healthcare.
Professor Chris Yau
University of Oxford
Dr David Morris
King's College London
Dr Dominik Glodzik
Harvard Medical School
The research of this community will seek to identify novel variant-trait associations and identify where such genotypic information can be leveraged for clinical application; such as the provision of polygenic risk scores and development of screening and treatment strategies. Particular attention will be given to the analysis of ancestries underrepresented in genomic research. This community will implement and improve tools for such analyses.
Professor Diana Baralle
University of Southampton
Dr Gavin Arno
University College London
Dr Hywel Williams
Cardiff University
Research in this community will explore the social, economic, legal, and ethical effectiveness of Genomic Medicine in the NHS, as well as work to improve data quality and availability.
Professor AJ McKnight
Queen’s University Belfast
Professor Claire Shovlin
Imperial College London
The Pan-Cancer and Molecular Oncology community will carry out research across all tumour and germline samples present in the NGRL. It will use the data to identify and investigate driver mutations across tumours, to find functional alterations and impaired biological mechanisms common to all/many cancers, and to establish whether there are common mutational signatures that affect treatment efficacy and toxicity
Professor Richard Houlston
Institute of Cancer Research
Professor Anna Schuh
University of Oxford
Professor Matt Lechner
University College London
This research aims to improve our understanding of human genetic variation and the processes that shape it, such as demography, ancestry, natural selection and genetic mutation. It also aims to elucidate the genomic contribution to disease and health in the population, and to inform diagnosis, treatment and the potential impact of interventions.
Dr Aylwyn Scally
University of Cambridge
Professor Jean-Baptiste Cazier
Francis Crick Institute
The Predisposition and Screening community will analyse genome data from families and individuals in the NGRL, including participants in the Generation Study and Diverse Data initiative, to identify de novo and inherited variants causing or predisposing to disease in diverse ancestries.
Professor Elijah Behr
St George's University
Professor Sanjay Sisodiya
University College London
This community will support research that propels genomic and clinical insight and discovery into therapeutic development and application.
Professor Danny Gale
University College London
Professor Haiyan Zhou
University College London
Professor Jenny Taylor
University of Oxford
Research in this community will strive to provide molecular diagnoses for participants by identifying or validating variants that explain previously undiagnosed cases and feeding these discoveries back into clinical practice via the appropriate pathways. New tools and data will be leveraged to tackle challenges and improve of ability to rapidly and reliably identify disease variants.
Professor Sophie Hambleton
Newcastle University
Professor Claude Chelala
Queen Mary University of London
Dr Alisdair McNeill
Sheffield Children’s Hospital NHS Foundation Trust
Browse existing GECIP domains
Use the menu to find information about each domain and research using data from the National Genomic Research Library.
The impact of collecting and using patient data isn't always straightforward, so we're always listening to public opinion and leading the ethics debate.
Watch this short video on the public dialogue around screening the whole genomes of newborns.
The NHS Genomic Medicine Service (GMS) Research Collaborative is a partnership between the NHS GMS, Genomics England and the National Institute of Health Research (NIHR) to support genomic research and development on a national scale.
Chang L
Garcia-Salinas OI
Babai A